Lipogen is expanding its production facilities and building a new phospholipids research and development centre in response to what the company says is a rapid, 50% jump in sales of brain and stress health solutions.
Lipogen is expanding its production facilities and building a new phospholipids research and development centre in response to what the company says is a rapid, 50% jump in sales of brain and stress health solutions in Q1-Q3 2015.Lipogen invested $2.6 million in building two additional production lines for PhosphatidylSerine (PS) and Phosphatidic Acid (PA). The company also added 10,000 sq.ft. to its facilities to double production capabilities for PS and PA. Upgrades include automated controlled processing to reduce production costs through improved production traceability, and implementing new safety methods, allowing Lipogen, the company said, to produce its all-natural, non-GMO, solvent-free ingredients in accordance with the highest industry standards.According to Lipogen, the PS market is forecast to grow significantly due to developments of new applications plus a growing demand in emerging markets, such as India and China. The company notes that data from Nutrition Business Journal put the US cognitive health market at US$1.2 billion by 2014, up from just under US$1 billion in 2010. NBJ estimates the market will hit almost US$1.5 billion by 2020.“Increasing demand for our brain health and stress management ingredients pushed us to establish a new growth strategy for our PS and PA product line,” saidDavid Rutenberg, CEO of Lipogen. “The phospholipids market is expanding from traditional brain function support to new brain health concepts, including: stress management, cortisol control, ADHD mitigation, sports nutrition and more.”Lipogen says it continues to research and develop new cognitive and stress management solutions based on proprietary technology and enzymatic process. The phospholipids R&D centre was designed to support product development and product research at Lipogen facilities. The company has appointed Abraham Rutenberg as VP and R&D manager. In addition, Lipogen expanded its headquarters, appointing Ariel Gordon as VP Business Development manager to develop new segments and markets for Lipogen’s brands.“I’m excited to welcome Abraham Rutenberg and Ariel Gordon to our team,” said Rutenberg. “They will lead Lipogen to the next level via high-impact growth—not only in the dietary supplements industry, but also in the food, beverage and pharmaceuticals industries. Lipogen is committed to producing pure, high-quality products with minimal damage to the environment. We’ve initiated a long-term sustainability strategy for our complete product line.”